{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:37:00Z","timestamp":1790775420456,"version":"4.1.0"},"reference-count":17,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA28824"],"award-info":[{"award-number":["CA28824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We conducted a phase I study in ovarian cancer patients to evaluate the safety and immunogenicity of a synthetic unimolecular pentavalent carbohydrate vaccine (Globo-H, GM2, sTn, TF, and Tn) supported on a peptide backbone, conjugated to keyhole limpet haemocyanin (KLH), and mixed with immunological adjuvant QS-21. Twenty-four advanced-stage, poor-risk, first-remission ovarian cancer patients were enrolled from January 2011\u2013Septermber 2013. Three dose levels were planned (25, 50, 100 mcg) with three cohorts of six patients each, with an additional 6-patient expansion cohort at the MTD. ELISA serologic IgM and IgG responses for each antigen was defined as positive response if antibody titers were \u22651:80 over the respective patient\u2019s pre-vaccination serum. The study would be considered positive if at least four of 12 patients treated at the MTD showed immune responses for at least three of the five antigens. Twenty-four patients (median age, 54 years [range, 36\u201368]) were included in the safety analysis. Histology was high-grade serous in 22 patients (92%); 18 had stage III and six stage IV disease. The vaccine was well-tolerated at all doses, with no DLTs. At the highest treated dose, IgG and\/or IgM responses were recorded against \u22653 antigens in 9\/12 patients (75%), \u22654 in 7\/12 (58%), and 5 in 3\/12 (25%). With a median follow-up of 19 months (range, 2\u201339), 20 patients (83%) recurred and six (25%) died. The unimolecular pentavalent vaccine construct was shown to be safe and immunogenic. Such a construct greatly simplifies regulatory requirements and manufacturing, facilitates scalability, and provides adaptability.<\/jats:p>","DOI":"10.3390\/cancers8040046","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T09:55:00Z","timestamp":1461578100000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission"],"prefix":"10.3390","volume":"8","author":[{"given":"Roisin","family":"O\u2019Cearbhaill","sequence":"first","affiliation":[{"name":"Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-8520","authenticated-orcid":false,"given":"Govind","family":"Ragupathi","sequence":"additional","affiliation":[{"name":"Melanoma & Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wan","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Mironov","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbin","family":"Yang","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Spassova","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kravetz","sequence":"additional","affiliation":[{"name":"Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouathek","family":"Ouerfelli","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[{"name":"Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Danishefsky","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_2","first-page":"2069","article-title":"Advanced epithelial ovarian cancer: From standard chemotherapy to promising molecular pathway targets\u2014where are we now?","volume":"34","author":"Syrios","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2005.04.5138","article-title":"Consolidation for ovarian cancer in remission","volume":"24","author":"Sabbatini","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"2669","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: Protein antigens","volume":"4","author":"Zhang","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.4049\/jimmunol.174.9.5706","article-title":"Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity","volume":"174","author":"Ragupathi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<193::AID-IJC5>3.0.CO;2-S","article-title":"Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: Serous and mucinous tumors exhibit distinctive patterns of expression","volume":"81","author":"Federici","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group related antigens","volume":"73","author":"Zhang","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.051626298","article-title":"Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial","volume":"98","author":"Gilewski","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","first-page":"874","article-title":"Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study","volume":"6","author":"Chapman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/1097-0215(20000701)87:1<79::AID-IJC12>3.0.CO;2-L","article-title":"Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: A phase 1 trial","volume":"87","author":"Sabbatini","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00262-004-0584-y","article-title":"Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn","volume":"54","author":"Kagan","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00262-004-0598-5","article-title":"Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer","volume":"54","author":"Slovin","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/ja057244+","article-title":"Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: A synthetic route to anticancer vaccine candidates","volume":"128","author":"Ragupathi","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9298","DOI":"10.1021\/ja901415s","article-title":"From synthesis to biologics: Preclinical data on a chemistry derived anticancer vaccine","volume":"131","author":"Zhu","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0006-2952(94)90554-1","article-title":"Schedule dependence of sensitivity to2\u2032,2\u2032-difluorodeoxycytidine in relation to accumulation and retention of its triphophate in solid tumor cell lines and solid tumors","volume":"48","author":"Veerman","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2307\/2533060","article-title":"Optimal sample size for a series of pilot trials of new agents","volume":"52","author":"Yao","year":"1996","journal-title":"Biometrics"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/8\/4\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:22:43Z","timestamp":1760210563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/8\/4\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"alternative-id":["cancers8040046"],"URL":"https:\/\/doi.org\/10.3390\/cancers8040046","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]}}}